Add onc brain to your Home Screen: tap Share, then Add to Home Screen.
TORPEdO: IMPT vs IMRT chemoRT in locally advanced OPSCC, 12-mo tube dependence/severe weight loss 18% vs 7% (p=0.079), UW-QoL 78.3 vs 77.1 (p=0.56), no functional gain.
The one head-neck readout: TORPEdO, a phase 3 RCT of IMPT vs IMRT (N=205, 70 Gy/33 fx + cisplatin). Protons lowered OAR doses but gave no 12-mo functional gain. Tube dependence/severe weight loss was 18% vs 7% (p=0.079) and UW-QoL 78.3 vs 77.1 (p=0.56). Weigh this against missed fractions in 49% of IMPT pts and a two-centre pathway confound.
read the full digest →Studies · 129
- TORPEdOIMPT vs IMRT in locally advanced OPSCC: 12-mo tube dependence/severe weight loss 18% vs 7% (p=0.079), UW-QoL 78.3 vs 77.1 (p=0.56).
- PROTEUS5-yr BCR-FS 44%, MFS 71%, CSS 92% at 60-mo median follow-up in a high-risk cohort.
- MARCAP ConsortiumIPD meta-analysis, 10,853 pts: ADT added to RT improved MFS HR 0.83 and OS HR 0.86; dose escalation improved bRFS only.
- STAR-TREC12-mo TME-free survival 78.5% with LCCRT vs 60.6% with SCRT, HR 1.90 (1.29-2.81), in mrT1-T3bN0 rectal cancer.
- Focal Ablation vs IMRT Toxicity (SEER-Medicare)GI toxicity favored focal therapy at 24mo (11.0% vs 21.5%, OR 0.45) but GU toxicity favored IMRT (41.7% vs 29.3%, OR 1.69).
- NRG-GU0053yr DFS 88.6% SBRT vs 92.1% MH-IMRT, superiority rejected (adjusted HR 1.40, 0.91-2.13); bowel and GU toxicity favored SBRT.
- Testosterone recovery post-ADT discontinuation (podcast review)Review of two datasets: 25% of real-world pts recovered T within 12mo; 54% relugolix vs 3% leuprolide at 90d in HERO.
- Moderately hypofractionated partial breast reirradiation40Gy/15fx PBI re-RT after second lumpectomy: 3yr LR-FS, DR-FS and OS all 86%, no grade 3+ late events (N=11).
- NSABP B-35 margin-width analysis10yr IBTR 5.6% vs 4.0% at 1mm cutoff (abs diff 1.6%), 5.3% vs 3.8% at 2mm (abs diff 1.5%).
- Cardiac Risk After Heart-Sparing Breast RadiotherapyMax LAD ≥12 Gy EQD2: sHR 1.81 (1.04-3.16) for cardiac events; mean heart dose ≥2 Gy null (P=.99), 2223 left-sided pts.
- Organs at Risk Radiation Dose Constraints: 2025 UpdateSFRO 2025 OAR dose-constraint update: normofractionated, moderate hypofractionated and ablative tables across skull base, H&N, lung, breast, oesophagus, liver.
- HERO90-day testosterone recovery to ≥280 ng/dL 53.9% with relugolix vs 3.2% with leuprolide after 48wk ADT.